2 Top Growth Stocks to Buy Right Now Without Any Hesitation
2026-07-24 04:30
•Prosper Junior Bakiny •The Motley Fool
••••••• •••••• Axe Capital view
Two Growth Stocks That Demand Attention Now
Eli Lilly and Intuitive Surgical stand out in healthcare with strong growth stories worth considering.
Eli Lilly has carved out a leadership slot in weight management, a market growing as global obesity rises. Their approved drugs like Zepbound and Foundayo aren’t just fads—they show real staying power and should drive steady revenue growth. Plus, their pipeline candidate retatrutide appears to be a game changer, potentially extending their lead. Meanwhile, Intuitive Surgical doesn’t get enough credit given the recent market pullback. The rollout of their da Vinci 5 platform upgrades their tech edge, reinforcing a tough competitive moat. Surgical robotics adoption is fast gaining traction, and with high costs to switch, Intuitive enjoys recurring revenue clarity. From a South African angle, these global pharma and med-tech leaders can offer exposure to dollar earnings, which is helpful given current rand volatility. The risk is these stocks’ valuation could get hit if regulatory hurdles slow approvals or if geopolitical tensions push the rand weaker against the dollar. Still, these are well-positioned growth plays in a defensive corner of the market—rare finds at the moment. this is just my opinion and not financial advice
I’d buy Eli Lilly and Intuitive Surgical on dips to capture their growth runway while keeping an eye on USD/ZAR moves. A rand weakening would bolster returns for South African investors holding these USD earners.
- LLY
- ISRG
- USD/ZAR
- Regulatory delays affecting drug approvals
- Volatile rand hurting USD-based returns
7/10
The article recommends Eli Lilly and Intuitive Surgical as outstanding healthcare stocks to buy. Eli Lilly is positioned as a leader in the rapidly growing weight management medicine market with approved drugs like Zepbound and Foundayo, plus promising pipeline candidates like retatrutide. Intuitive Surgical, despite recent underperformance and headwinds, is viewed as a buying opportunity due to the successful launch of its da Vinci 5 surgical system and strong long-term prospects driven by innovation and high switching costs.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Prosper Junior Bakiny
Categories: Regulation, Legal, Technology, AI, Semiconductors, Healthcare, Equities
Tickers: LLY, ISRG, JNJ, NVO, MRK, ABBV
Sentiment: Positive - Leading position in rapidly growing weight management market with approved products (Zepbound, Foundayo) showing strong performance, deep pipeline with promising candidates like retatrutide demonstrating superior efficacy, and broader pharmaceutical portfolio positioning it as a top-performing pharma giant with continued growth potential. Despite recent 33% underperformance and near-term headwinds (competition, tariffs, lower margins), the company benefits from successful da Vinci 5 launch with advanced capabilities, strong competitive moat due to high switching costs, 20+ years of real-world outcomes, and significant long-term opportunities in robotic-assisted surgery adoption and AI-assisted procedures.
Keywords: weight management, obesity epidemic, pharmaceutical, robotic-assisted surgery, healthcare stocks, pipeline, innovation, market opportunity
Insights:
- LLY: Positive: Leading position in rapidly growing weight management market with approved products (Zepbound, Foundayo) showing strong performance, deep pipeline with promising candidates like retatrutide demonstrating superior efficacy, and broader pharmaceutical portfolio positioning it as a top-performing pharma giant with continued growth potential.
- ISRG: Positive: Despite recent 33% underperformance and near-term headwinds (competition, tariffs, lower margins), the company benefits from successful da Vinci 5 launch with advanced capabilities, strong competitive moat due to high switching costs, 20+ years of real-world outcomes, and significant long-term opportunities in robotic-assisted surgery adoption and AI-assisted procedures.
- JNJ: Neutral: Mentioned only in disclosure statements regarding analyst positions and Motley Fool recommendations; no substantive analysis or investment thesis provided in the article.